DPP4 and Hypoglycemia: Additionally, a review of randomized controlled trials (1974–2012 years) of DPP-4 inhibitors and metformin found that DPP-4 inhibitors had smaller effect on HbA1c (MD = 0.28), FPG (MD = 0.81), and weight loss (MD = 1.51) but were more effective in reducing the risk of cardiovascular events (RR = 0.36), hypoglycemia (RR = 0.44), and gastrointestinal side effects (RR = 0.63).